The sections below explain what the hormone measures, how to read a result against typical and optimal ranges, which factors genuinely move it in either direction, and what a high or low number is worth raising with a clinician.
Anti-Müllerian hormone (AMH) is a protein released by the granulosa cells that surround small, early-stage follicles in the ovary, so the blood level works as an indirect count of how many of those follicles are currently active[1].
Each small follicle contributes a little hormone to the circulation. Add those contributions together and you get a number that tracks the size of the growing follicle pool, which is then used as a proxy for ovarian reserve[2]. Two things follow from that. First, it is a measure of quantity, not of egg quality, and not of whether any single cycle will produce a healthy embryo. Second, it is relatively stable across the menstrual cycle, because it comes mainly from follicles that sit below the stage where FSH drives the big mid-cycle swings[2].
Production is also controlled locally, inside the follicle itself. Laboratory work in granulosa cells shows AMH expression responding to intra-ovarian signalling molecules, including BMP6 acting through SMAD1/5/8 pathways[3]. That is part of why there is no simple external lever that instructs the ovary to produce more. The signal is downstream of how many follicles exist and what is happening inside them.
In men, the same hormone is made by Sertoli cells in the testes and carries a different meaning, which is covered further down.
Because it is the most practical quantitative marker of ovarian reserve available from one blood draw, and it predicts how the ovaries are likely to respond to stimulation during fertility treatment[1]. Reviews of ovarian reserve testing describe it as useful for planning assisted reproduction, for counselling before and after treatments that can damage the ovary, and as one input when assessing polycystic ovary syndrome[2].
What it does not do matters just as much. A low result does not mean conception is impossible, and a high result is not a guarantee of anything. Research suggests it is a weak predictor of how long natural conception takes in people without a known fertility problem, which is why it is better treated as a planning signal than a verdict[1].
Levels also decline with age, tracking the broad trajectory toward menopause at a population level. That is a population pattern, not a personal countdown clock, and individual variation is wide.
The honest framing is this. The number tells you something real about the current size of the follicle pool. It does not tell you whether a particular person will conceive, and it does not respond to effort the way cholesterol or fasting glucose might.
Most laboratories report a broad adult reference interval, and optimization targets sit inside it. Here is how the two compare.
| Measure | Typical lab reference range | FitScript optimal range |
|---|---|---|
| AMH (adult, general) | 0.5 to 6.5 ng/mL | 1 to 4 ng/mL |
| AMH (women) | 0.5 to 6.5 ng/mL | 1 to 4 ng/mL |
| AMH (men) | 0.5 to 8 ng/mL | 1 to 5 ng/mL |
Reference ranges are typical lab reference ranges and vary by laboratory, assay, age and sex. The optimal ranges shown are FitScript's optimization targets, not diagnostic cut-offs, and a result outside them is not a diagnosis of anything.
Age is the single biggest driver of where a result falls. Reviews of serum AMH distributions describe clear age-specific patterns, with levels generally highest in early reproductive years and declining afterwards, alongside reported variation between ethnic and racial groups[4]. A result that looks unremarkable for one age can be notably low for another, so the number should always be read against age rather than against a single population range.
Units matter too. Many laboratories report in pmol/L rather than ng/mL, so check which unit is on your report before comparing two results from different labs.
A low reading most often reflects a smaller pool of small, growing follicles, which is the normal consequence of age, but several other explanations exist and some are reversible.
Severe endometriosis involving the ovary is also associated with lower readings.
Reversible or artefactual contributors are the ones worth ruling out first. Combined hormonal contraception is associated with suppressed levels while it is being used, and readings commonly rise again after it is stopped. Recent pregnancy, lactation and recent ovarian stimulation can also shift a result. So can an assay change between two labs.
The practical way to read it is observation, then meaning, then next step. The observation is a number below what is typical for your age. The meaning is that it may reflect a smaller current follicle pool, or a temporary suppression, or a measurement issue. The next step is to put it beside age, cycle history, surgical history and a second marker before drawing any conclusion, and to discuss an unexpectedly low result with a clinician rather than acting on it alone[1].
An elevated reading most often reflects a large number of small antral follicles, which is a defining ovarian feature of polycystic ovary syndrome[5]. It can also simply reflect a younger age or a naturally generous follicle pool.
In PCOS, the relationship is more than incidental. Research describes AMH as directly involved in the disordered follicle development seen in the condition, not merely a passive readout of follicle number[5]. That is one reason a high value in someone with irregular cycles, acne or unwanted hair growth is worth a full clinical assessment rather than a shrug.
Higher is also not automatically better. In a human ovarian xenograft model, chronically superphysiologic AMH exposure promoted premature luteinization of antral follicles, which is a reminder that this hormone has active roles in follicle behaviour rather than being a simple scoreboard[6].
A high result also has a practical implication in fertility treatment, where it flags a stronger likely response to ovarian stimulation. That is information a fertility clinician uses when deciding how to approach a cycle, and it is a decision only a licensed provider can make after reviewing the full picture.
No intervention is known to reliably increase the underlying follicle pool, which is what the hormone reports on. The honest answer is that a truly low result reflects biology that current medicine cannot reverse, and anything promising otherwise is overpromising.
Two points make this clearer. First, the signal is generated at the level of individual follicles and regulated by local intra-ovarian pathways[3], so there is no systemic switch that increases output on demand. Second, the marker behaves as a stable, repeatable indicator of follicle reserve across species. Work in domestic and agricultural animals uses it precisely because it is consistent within an individual and predicts response to superovulation[7][8]. A marker that is useful because it is stable is, by definition, not a marker that moves easily with lifestyle.
What can change is the measured value when something was artificially holding it down. That distinction matters. Removing a suppressor and seeing a reading rise is not growing new follicles, it is seeing the existing pool more accurately.
So the realistic goals are to get an accurate measurement, to understand what it means for your timeline, and to protect the reserve you have rather than chase the number itself.
Several common situations suppress the measured value without changing the underlying reserve, and checking for them is the first useful step after an unexpected result.
The practical move is simple. If any of these applies, note it on the result, then plan a repeat test on the same assay once the situation has changed, rather than treating the first number as final.
Metabolic health does not grow new follicles, but it can influence where a reading sits, and it is clearly worth attention in its own right.
The clearest signal comes from PCOS, where insulin resistance and AMH levels are linked. Research in women with PCOS reports associations between serum AMH and markers of insulin resistance[10]. In that setting, work that improves insulin sensitivity, including nutrition, resistance and aerobic training, sleep and, where a licensed provider judges it appropriate, insulin-sensitising medication, is associated with improvement in the broader hormonal picture. A previously elevated value may drift downward as follicle dynamics normalise, which is a favourable direction in that context rather than a loss.
In people without PCOS, it is not established that body weight or diet meaningfully changes the number. Very low energy availability, heavy smoking and significant illness are all plausibly unhelpful for ovarian function, but none of them offers an upward lever on a result that is genuinely low for age.
The realistic framing is protective rather than restorative. Good metabolic health, not smoking, adequate nutrition, sensible training load and treated thyroid disease support ovarian function generally. They are not a method for rebuilding reserve, and they should not be sold as one.
None of these is known to reliably raise AMH, and the strongest claims in this area are not established.
DHEA is an androgen precursor that has been studied in people with diminished ovarian reserve undergoing fertility treatment. Results are mixed, much of the work is small, and it is a hormonal intervention rather than a benign vitamin. A licensed provider evaluates whether any hormonal supplement or prescription therapy is appropriate, and monitoring matters when androgens are involved.
CoQ10 has been studied for mitochondrial support in oocytes, with most interest focused on treatment response rather than on moving the marker itself. Whether it helps is not settled.
The effect of vitamin D here is uncertain. Correcting a documented deficiency is sensible for broader health, which is a reasonable thing to check regardless, but expecting a deficiency correction to lift ovarian reserve is not supported.
Myo-inositol is often discussed in PCOS, although a systematic review informing the 2023 international PCOS guideline judged the evidence on its effects limited and uncertain[13]. Where it does change the reading, that would plausibly follow improved insulin signalling rather than an increase in follicle number.
The common thread is that supplements may support general reproductive health, and none of them reverses age-related decline. Anything with hormonal activity belongs in a conversation with a clinician before it is started.
Several medical interventions clearly move the measured value, and almost all of them move it downward, which is why the clinical priority is protection rather than elevation.
Chemotherapy with gonadotoxic agents and pelvic radiation can reduce ovarian reserve, sometimes substantially, and falling levels are used to monitor that damage[2]. Interestingly, preclinical research suggests the hormone itself plays a protective role in the ovary during exposure to the chemotherapy agent doxorubicin, by influencing cell fate and the DNA damage response[11]. That is early, laboratory-stage science and not a treatment available to patients, but it supports the idea that the molecule is an active participant in ovarian biology.
Ovarian surgery, particularly repeated cystectomy, removes functional tissue and tends to lower subsequent readings. Hormonal contraception and pituitary-suppressing medications lower it reversibly while in use.
In the other direction, the main realistic upward movement is recovery of a suppressed reading after a suppressor is withdrawn.
Anyone facing cancer treatment or planned ovarian surgery who wants to preserve future options should raise fertility preservation with their care team before treatment starts, because the window matters. Whether any such option is appropriate is assessed by a licensed provider.
Testing is a standard serum blood draw, and because the hormone is relatively stable across the menstrual cycle, the sample can usually be taken on any day[2].
Two technical points improve the quality of the information. First, repeat tests should use the same laboratory and assay wherever possible. A large multicentre study examining the reliability of AMH and antral follicle count measurements, and the correlation between them, underlines that both are measurements with their own variability and should be interpreted together rather than in isolation[9]. Second, note anything on the day that could suppress the value, including current contraception or recent pregnancy, and record it next to the result.
The result is most informative when it is read alongside an antral follicle count on transvaginal ultrasound, which counts visible small follicles directly. Where the two agree, confidence rises. Where they disagree sharply, that disagreement is itself useful and worth investigating.
FitScript's membership includes 150+ biomarkers tested per year, with results interpreted by Atlas, FitScript's AI health advisor, and any treatment decision made by a licensed provider after reviewing the member. Repeat testing intervals are set with a clinician based on your situation, not on a fixed calendar, and retesting frequently in the hope of a better number tends to produce noise rather than insight.
Work through context first, then confirmation, then meaning, then decisions. In that order.
The aim throughout is accuracy and timing, not a higher number.
Ovarian reserve is never well described by one value, so the useful panel includes markers that fill in what this one cannot[1].
Tested together, these turn a single ambiguous number into a readable pattern.
In men the hormone comes from Sertoli cells in the testes, and it is a marker of Sertoli cell function rather than of fertility or sperm count.
Levels are high in boys before puberty and fall as testosterone rises during puberty, which is why values are interpreted strictly against age and pubertal stage. In paediatric medicine, this makes it a valuable test for assessing whether functional testicular tissue is present, and it is used in the workup of disorders of sex development and of undescended or absent testes[12].
In adult men, the measurement is used far less often. It is not a substitute for a semen analysis, and it does not tell you about testosterone status, which is assessed with its own panel. A result outside the typical range in an adult man is best interpreted alongside testosterone, LH, FSH and clinical findings rather than on its own.
For men, as for women, the number is a structural readout. It describes the cells producing it rather than something to be optimised in isolation.
Any result that is clearly outside the typical range for your age deserves a clinical conversation, and some situations deserve one promptly rather than at the next routine visit.
Book a prompt conversation if a low result comes with irregular or absent periods, hot flushes or night sweats at a young age, or a history of ovarian surgery, cancer treatment or pelvic radiation. The same applies if a high result sits alongside irregular cycles, acne, unwanted hair growth or difficulty conceiving, since that combination is worth a proper PCOS assessment rather than self-interpretation[5].
Also raise it early, rather than later, if you are considering pregnancy in the future and want the result to inform timing. Information is most useful when there is still room to act on it.
What never helps is ignoring a result that sits outside the range, or treating a single value as a verdict. Bring the number, the context and the supporting markers to a clinician or licensed provider, and discuss your results and any proposed treatment with them before changing anything. This page is educational and not medical advice.
For marker-level detail, the AMH page covers how the result is produced and read, FSH explains the pituitary side of follicle recruitment, estradiol shows why an early-cycle pairing changes the interpretation, and progesterone addresses whether ovulation actually occurred in a given cycle. The FitScript Complete panel for women page sets out which of these are tested together.
You generally cannot. AMH reflects how many small follicles remain, and no supplement or lifestyle change reliably increases that pool. What can rise is a reading that was suppressed by hormonal contraception, recent pregnancy or pituitary-suppressing medication. Removing a suppressor, with clinician guidance, and retesting on the same assay often gives a truer value.
Focus on accuracy rather than elevation. Confirm the result on the same assay, note any contraception, recent pregnancy or ovarian surgery, and pair it with an antral follicle count and early-cycle FSH and estradiol. If a genuinely low level affects your plans, discuss timing and options with a fertility clinician sooner rather than later.
There is no established method of increasing this hormone, because it is produced by follicles that already exist and is regulated locally inside the ovary. Protective steps matter more. Avoid smoking, address insulin resistance and thyroid problems, and raise fertility preservation with a licensed provider before any planned ovarian surgery or gonadotoxic treatment.
Treat the number as information, not a target. Supplements marketed for this purpose have uncertain effects, and anything hormonal is evaluated by a licensed provider before use. The reliable gains come from removing suppressors, correcting measurement issues and testing supporting markers alongside it.
A suppressed reading can improve, and a genuinely depleted reserve generally cannot. Values commonly rise again after stopping combined hormonal contraception or after a period of pituitary suppression ends. That rise reflects a more accurate measurement of the existing follicle pool rather than new follicles being created.
Often yes. Combined hormonal contraception is associated with lower measured levels while it is being used, and readings commonly recover afterwards. If a result was taken during contraceptive use, note that on the report and plan a repeat test with your clinician once your cycles have settled, using the same laboratory.
Not in adults. Levels are generally highest during early reproductive years and decline with age. An apparent rise between two tests is more likely to reflect a different assay, a removed suppressor or normal measurement variation than a genuine increase in reserve.
No. A low value indicates a smaller pool of small growing follicles, which predicts response to ovarian stimulation better than it predicts natural conception. Many people with low readings conceive naturally. It is a planning signal worth discussing with a clinician, not a conclusion about whether pregnancy is possible.
Retesting intervals are set with your clinician based on age, goals and what changed since the last test. Frequent repeat testing tends to produce assay noise rather than insight. Use the same laboratory each time, and pair the blood result with an antral follicle count for a more complete picture.